Biosciences
AIB-BIOSCIENCES conservative long-term HITL-dynamicAI-generated Index Basket · theme “human biology + drug discovery + bioinformatic + computational biology + biotechnology + pharmaceutical + drug design” · 10 components selected by the Tuatara vector model.
Trade AIB-BIOSCIENCES on the Pro Terminal → Join the Biosciences channel on Telegram → Join the Biosciences channel on Discord → Apply to the Tuatara Hedge Fund →
$83.29
+4.78%
10
2026-08-14
Performance
$ index price history since inception.
Real-time index and orderbook are on the
pro terminal.
Profile
Biosciences (AIB-BIOSCIENCES)
conservative long-term
price-weighted
Tuatara vector network proposes · Human-In-The-Loop approves
2026-08-14
human biologydrug discoverybioinformaticcomputational biologybiotechnologypharmaceuticaldrug design
Dynamic portfolio: the Tuatara vector network continuously re-measures each component’s relevance to the fund’s theme — including hidden connections the obvious sector lists miss. Component hot-swaps are proposed by the model network and executed only with Human-In-The-Loop approval — a conservative, long-term governance loop modeled on cell–cell signal transduction. The index series stays continuous through every approved change.
Ontology & Supply Chain
The controlled vocabulary governing this fund — category → class → subclass, plus the sector’s supply chain. The Tuatara Vector Model measures every concept against the live stock and crypto universe; asset chips show human-curator-approved connections only. Full graph for all seven funds: AIB Ontology Graph.
direct connection
hidden connection
→ supply-chain flow, upstream to downstream
Ontology — controlled vocabulary
-
Human aging & healthspan
aib-biosciences-aging-healthspan
longevity biology and healthspan-extension research and interventionsISCO stock
-
CRO/CDMO & biomanufacturing
aib-biosciences-cro-cdmo-biomanufacturing
outsourced clinical research and drug/biologic contract development and manufacturing services
-
Drug discovery & development
aib-biosciences-drug-discovery
the research-to-clinic pipeline for new therapeuticsABSI stock
-
AI/computational drug design
aib-biosciences-drug-discovery-ai-design
machine-learning-driven target identification, molecule generation and in-silico screeningABSI stock
-
Clinical-stage modalities
aib-biosciences-drug-discovery-clinical-modalities
small-molecule, biologic and RNA candidates in preclinical through Phase III trials
-
AI/computational drug design
aib-biosciences-drug-discovery-ai-design
-
Drug repurposing
aib-biosciences-drug-repurposing
identifying new therapeutic uses for existing approved compoundsVITA-FAST crypto
-
Gene & cell therapy
aib-biosciences-gene-cell-therapy
cellular and genetic therapy products: viral-vector gene therapy, CAR-T and stem-cell therapeutics
-
Genomics & sequencing
aib-biosciences-genomics-sequencing
DNA/RNA sequencing platforms and genome-scale data generation underpinning genomic medicine
-
Synthetic biology & genome engineering
aib-biosciences-genomics-sequencing-synbio
engineered DNA, gene circuits and genome-editing tools for biomanufacturing and therapeuticsTWST stock GROW crypto
-
Synthetic biology & genome engineering
aib-biosciences-genomics-sequencing-synbio
-
Life sciences tools & lab instrumentation
aib-biosciences-lab-tools-instruments
analytical instruments, reagents, consumables and lab automation enabling the R&D-to-production continuum
-
Multiomics & Spaceomics
aib-biosciences-multiomics-spaceomics
integrated genomic, proteomic and metabolomic data science, including space-biology omics
-
Pharma/Biotech
aib-biosciences-pharma-biotech
the broad pharmaceutical and biotechnology company universe
-
Precision medicine & diagnostics
aib-biosciences-precision-diagnostics
genotype- and biomarker-guided diagnostics and treatment selection, including companion and molecular diagnostics
-
Spatial transcriptomics
aib-biosciences-spatial-transcriptomics
gene-expression mapping with preserved tissue spatial contextLAB stock TECH stock TXG stock
ISCO
stock
COR
stock
SER
stock
RNA
stock
EVGN
stock
QGEN
stock
BIO
stock
HTFL
stock
STVN
stock
NNVC
stock
Supply chain
STAGE 1
Research inputs & instruments
lab reagents, sequencing hardware and analytical instrumentation that generate biological data
→
STAGE 2
Discovery
target identification, computational/AI drug design and candidate generation
→
STAGE 3
Preclinical & clinical development
IND-enabling studies through Phase I–III trials, including CRO-run trial management
→
STAGE 4
Manufacturing (CDMO/bioprocessing)
contract development and manufacturing of drug substance and product, biologics and cell/gene-therapy vectors
→
STAGE 5
Regulatory approval
FDA/EMA review and licensure of drugs, biologics and cell/gene-therapy products
→
STAGE 6
Commercialization & distribution
market launch, sales and supply distribution of approved products
→
STAGE 7
Care delivery
diagnostics-guided treatment selection and clinical administration to patients
Holdings
| Component | Connection | Weight | Relevance | |
|---|---|---|---|---|
| BIO | direct | 45.06% | 1.000 | |
| COR | direct | 39.31% | 1.000 | |
| QGEN | direct | 5.40% | 1.000 | |
| HTFL | direct | 5.31% | 0.609 | |
| STVN | direct | 2.66% | 0.526 | |
| RNA | direct | 1.61% | 1.000 | |
| SER | direct | 0.35% | 1.000 | |
| NNVC | direct | 0.17% | 0.441 | |
| EVGN | direct | 0.08% | 1.000 | |
| ISCO | direct | 0.04% | 1.000 |
Holdings are disclosed by
design — this is the tradable index. direct = the component’s
core business is the theme; hidden = a real but non-obvious
supply-chain or second-order connection surfaced by the vector model.
Relevance is the Tuatara affinity score (0–1, normalized).
Recent signals
| hackernews | Who owns the code? AI code == no author == no copyright |
| hackernews | I should have loved biology (2020) |
| techcrunch | Google packs Search and Gemini with new AI study tools |
| hackernews | Don't Paste the AI, please |
| hackernews | Os8088.com: IBM XT OS now has a Browser, CP/M 2.2 with Z80 core and MS Word 1.1a |
News and research events the
platform’s signal layer linked to this fund’s components —
inputs that prioritize the next portfolio re-measure. Signals never
trade by themselves.